MEAK7

Across TCGA pan-cancer cohorts, MEAK7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEAK7 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MEAK7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MEAK7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where MEAK7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	7	view →
PDAC	DFS	Median	III,IV	0.570	0.786	.010	7	view →
LSCC	OS	Tertile	All	0.725	0.937	.008	5	view →
CCRCC	DFS	Tertile	III,IV	0.887	0.198	.024	3	view →
GBM	OS	Median	All	0.856	0.776	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEAK7–LUAD (DFS)

Open the LUAD breakdown →